Franklin Templeton filed for two Bitcoin DRIP ETFs this week, a move that blends old-school dividend investing with cryptocurrency. The funds would automatically take dividends paid out by the ETF's stock holdings and use that cash to buy Bitcoin. It's a twist on the classic dividend reinvestment plan — but with BTC as the destination instead of more shares.
How the DRIP works
The structure is straightforward: the ETF holds a portfolio of dividend-paying stocks. When those stocks pay out, the cash doesn't go to investors. Instead, it's funneled into Bitcoin purchases. Investors get exposure to both a traditional equity income stream and a growing Bitcoin position — without having to manually reinvest or manage a separate crypto wallet.
Franklin Templeton isn't new to crypto. The firm launched a spot Bitcoin ETF in 2024 and has been pushing into blockchain-based funds. These DRIP ETFs take that a step further, marrying two investor habits: collecting dividends and accumulating Bitcoin.
The filing signals that large asset managers see a market for products that don't force investors to choose between stocks and crypto. It could nudge more conservative money into Bitcoin — people who like the idea of digital gold but want a dividend check while they wait. If approved, these ETFs would be among the first to tie a recurring fiat income stream directly to Bitcoin accumulation.
That could boost adoption, especially among income-focused retail investors and maybe even some institutions looking for a way to dip into crypto without a separate allocation.
The volatility trade-off
There's a catch. Bitcoin's price swings are brutal. A dividend reinvestment plan that buys BTC on a schedule doesn't smooth out those moves — it just adds more Bitcoin when the price is low and less when it's high, which is standard dollar-cost averaging. But the underlying ETF's share price would reflect both the stock portfolio and the Bitcoin holdings. If Bitcoin drops 30%, the whole fund takes a hit, regardless of how steady the dividend stocks are.
Franklin Templeton's prospectus will likely spell out those risks. The filing didn't specify which stocks the ETFs would hold or the expense ratios.
The ETFs remain subject to regulatory review, with no timeline for approval yet.
